This study is designed to assess the antitumor efficacy and safety of pembrolizumab in
combination with BCG, compared to BCG monotherapy, in participants with HR NMIBC that is
either persistent or recurrent following adequate BCG induction (Cohort A), or that is naïve
to BCG treatment (Cohort B). The primary hypothesis for Cohort A is that the combination of
pembrolizumab plus BCG has a superior complete response rate (CRR) as assessed by central
pathology review compared to BCG in participants with carcinoma in situ (CIS). The primary
hypothesis for Cohort B is that the combination of pembrolizumab plus BCG (either reduced
maintenance or full maintenance) has a superior Event Free Survival (EFS) compared to BCG.

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

Burlington

University of Vermont Medical Center ( Site 1057)

Pembrolizumab

A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) That is Either Persistent or Recurrent Following BCG Induction or That is Naïve to BCG Treatment (KEYNOTE-676)

The purpose of the study is to assess the safety and tolerability of UCB0599 and to
demonstrate the superiority of UCB0599 over placebo with regard to clinical symptoms of
disease progression over 12 and 18 months in participants diagnosed with early-stage
Parkinson's Disease.

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

Pd0053 50107

UCB0599

Placebo

A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson's Disease

To test the effectiveness and safety of Optune® given concomitantly with radiation therapy
(RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy
and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued
following radiation therapy.

Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

The University of Vermont Medical Center - University of Vermont Cancer Center

Optune®

EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

This is a 1-year open-label study to access the safety of REL-1017 once daily (QD) as an
adjunctive treatment of Major Depressive Disorder. Study participants will continue to take
their current antidepressant therapy in addition to the study drug for the duration of the
treatment period.

Safety of REL-1017 for Major Depressive Disorder

Woodstock

Relmada Site 102

REL-1017

A Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder

The main purpose of this study is to assess is to evaluate the safety and efficacy of MK-1942
as adjunctive therapy in participants with mild to moderate Alzheimer's Disease (AD)
dementia.

Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)

Bennington

The Memory Clinic ( Site 0054)

MK-1942

A Phase 2a/2b Randomized, Placebo-Controlled Clinical Study To Evaluate The Safety And Efficacy Of MK-1942 As Adjunctive Therapy In Participants With Mild To Moderate Alzheimer's Disease Dementia

This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo
plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC),
all participants will receive the docetaxel with steroid therapy and receive androgen
deprivation therapy. The intention of the study is to demonstrate that the combination of
capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall
survival of study participants, when overall survival is defined as the time from
randomization until the date of death due to any cause.

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Research Site

capivasertib

docetaxel

placebo

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination
with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide
versus standard therapy alone for the treatment of poorly differentiated extrapulmonary
(originated outside the lung) neuroendocrine cancer that may have spread from where it first
started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has
spread from where it first started (primary site) to other places in the body (metastatic).
The other aim of this trial is to compare using atezolizumab just at the beginning of
treatment versus continuing it beyond the initial treatment. Immunotherapy with monoclonal
antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and
may interfere with the ability of tumor cells to grow and spread. Cisplatin and carboplatin
are in a class of medications known as platinum-containing compounds that work by killing,
stopping or slowing the growth of cancer cells. Etoposide is in a class of medications known
as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA
repair, and it may kill cancer cells. Giving atezolizumab in combination with a platinum drug
(cisplatin or carboplatin) and etoposide may work better in treating patients with poorly
differentiated extrapulmonary neuroendocrine cancer compared to standard therapy with a
platinum drug (cisplatin or carboplatin) and etoposide alone.

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Saint Johnsbury

Norris Cotton Cancer Center-North

Atezolizumab

Biospecimen Collection

Carboplatin

Cisplatin

Computed Tomography

Etoposide

Magnetic Resonance Imaging

Patient Observation

Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC #783608) in Patients With Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)

The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab,
carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) and amivantamab, carboplatin and
pemetrexed (ACP) compared with carboplatin and pemetrexed (CP) in participants with locally
advanced or metastatic epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R
substitution non-small cell lung cancer (NSCLC) after osimertinib failure.

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

University of Vermont Medical Center

Lazertinib

Amivantamab

Pemetrexed

A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure

This study is done to find out whether the medicine, semaglutide, has a positive effect on
early Alzheimer's disease.
Participants will either get semaglutide or placebo (a "dummy" medicine which does not
contain any study medicine) - which treatment participants get is decided by an equal chance.
The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have
17 clinic visits and 1 phone call with the study doctor. The study includes various tests and
scans. At 10 of the clinic visits participants will have blood samples taken.
Participants must have a study partner, who is willing to take part in the study.
Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study
period.
A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study
will be performed on a selection of sites based on their experience with CSF sampling and
willingness to participate in this sub-study. The endpoints related to this sub-study are
exploratory only.

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

Novo Nordisk Investigational Site

Semaglutide

Placebo (semaglutide)

A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE Plus)

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

Semagludtide

A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE)

Vermont